Atacand, Candesartan News

From the Program in Clinical and Experimental Therapeutics , University of Georgia College of Pharmacy, Veterans Administration Medical Center, Augusta, Ga; and the Departments of Physiology Biostatistics , Medical College of Georgia, Augusta Ga.

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease Eur Heart J , ehp101.

Abstract High levels of proteinuria predict renal deterioration, suggesting that interventions to reduce proteinuria may postpone the development of severe renal impairment.

Abstract OBJECTIVE: We evaluated the optimal dose of the angiotensin II receptor antagonist candesartan cilexetil for renoprotection as reflected by short-term changes in albuminuria in hypertensive type 2 ...

Azza B. El-Remessy RPh, PhD; Maribeth H. Johnson MS; Livia S. Machado BPharm; Hazem F. Elewa RPh; Mohammed Abdelsaid MS; Daniel C. Wiley BS; and Susan C. Fagan PharmD* From the Program in Clinical and ...

China Pharma Holdings, Inc. has begun a clinical trial of a generic version of the hypertension drug Candesartan.

February 12, 2009 - GenoMed announced today that AstraZeneca's study showing that high dose Atacand was better than low dose drug for patients with kidney failure fully supports results its CEO observed 15 ...

Taking a much higher than recommended dose of the hypertension drug candesartan cilexetil effectively lowered the amount of protein excreted in the urine of patients with kidney disease, according to a study ...

Large doses of AstraZeneca's high blood pressure drug Atacand may protect people with kidney disease from developing kidney failure and the need for dialysis or a transplant, researchers said Wednesday.

Company initiated clinical trials for leading hypertension drug in China a a HAIKOU CITY, China, Feb.

The decentralised procedure - including eleven EU member states and Iceland, and with Sweden as reference member state - ended positively, and national approvals will follow.

From the Department of Medicine , Harvard Medical School, Research Division, Joslin Diabetes Center, Boston, Mass; ActiveSite Pharmaceuticals, Inc , San Francisco, Calif; and Telehealth Research Institute , ...

ECARD is a tablet taken orally once daily and the two approved formulations are "ECARD LD" and "ECARD HD"; 4mg candesartan cilexetil / 6.25mg hydrochlorothiazide and 8mg candesartan cilexetil / 6.25mg ...

From the Department of Medicine , Harvard Medical School, Research Division, Joslin Diabetes Center, Boston, Mass; ActiveSite Pharmaceuticals, Inc , San Francisco, Calif; and Telehealth Research Institute , ...

Main Category: Heart Disease Also Included In: Genetics Article Date: 02 Jan 2009 - 3:00 PST A new clinical trial suggests that long-term use of candesartan, a drug currently used to treat hypertension, may ...

A new clinical trial suggests that long-term use of candesartan, a drug currently used to treat hypertension, may significantly reduce the symptoms of genetic heart disease.

Angiotensin II receptor blockers are used to treat conditions such as high blood pressure and heart failure.

Among heart failure patients with low ejection fraction and low systolic blood pressure, treatment with candesartan is still efficacious, according to the results of a clinical study reported in the Dec.